Bright Minds Biosciences Inc (DRUG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.50 Million) by net assets ($308.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DRUG defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Bright Minds Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bright Minds Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bright Minds Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zambal Spain Socimi SA
MC:YZBL
|
0.008x |
|
Sella Real Estate
TA:SLARL
|
0.021x |
|
SD Biosensor Inc
KO:137310
|
0.005x |
|
Dongwon F & B
KO:049770
|
0.026x |
|
Yingkou Jinchen Mach Co Ltd
SHG:603396
|
0.076x |
|
Cheng Uei Precision Industry Co Ltd
TW:2392
|
0.146x |
|
Sunplus Technology Co Ltd
TW:2401
|
0.018x |
|
Zhongjie (Jiangsu) Technology Co.Ltd.
SHE:301072
|
N/A |
Annual Cash Flow Conversion Efficiency for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bright Minds Biosciences Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Bright Minds Biosciences Inc (DRUG) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $82.04 Million | $-8.69 Million | -0.106x | +68.30% |
| 2024-09-30 | $5.54 Million | $-1.85 Million | -0.334x | +68.61% |
| 2023-09-30 | $6.60 Million | $-7.02 Million | -1.065x | +17.40% |
| 2022-09-30 | $10.54 Million | $-13.59 Million | -1.289x | -241.63% |
| 2021-09-30 | $19.40 Million | $-7.32 Million | -0.377x | +4.60% |
| 2020-09-30 | $729.29K | $-288.39K | -0.395x | -19.80% |
| 2019-09-30 | $127.26K | $-42.01K | -0.330x | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more